A double-blind, randomized, 6-week, parallel-group clinicaltrial to assess the safety and efficacy of Asacol 4.8 g/day(800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mgmesalamine tablet) for the treatment of moderately activeulcerative colitis (ASCEND III) - ASCEND III

Procter & Gamble Technical Centres Limited0 个研究点目标入组 770 人开始时间: 2006年5月17日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 770

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Patients, who
•a) are willing and able to provide written informed consent;
•b) are male or female between 18 and 75 years of age, inclusive, at Screening;
•c) have a confirmed diagnosis of moderately active ulcerative colitis, extending proximally beyond 15 cm from the anal verge, as confirmed by flexible sigmoidoscopy or colonoscopy performed within 7 days prior to the Baseline Visit.
•d) have a confirmed diagnosis of moderately active disease (PGA = 2, see Appendix 7.7) at the Baseline Visit;
•e) have, at the Baseline Visit, a score of at least 1 in both the stool frequency and rectal bleeding clinical assessments and a score of at least 2 in the Sigmoidoscopy Assessment Score (Appendix 7.3);
•f) if female, must be (as documented by verbally offered medical history):
•postmenopausal (at least 1 year without spontaneous menses), or
•surgically sterile (tubal ligation or hysterectomy at least 6 months prior to
•enrollment), or
•using acceptable contraception (e.g., oral, intramuscular, or implanted hormonal
•contraception [at least 3 months prior to enrollment], sexual partner with nonreversed vasectomy [with azoospermia in 2 tests], 2 barrier methods [e.g., condom, diaphragm, or spermicide], or intra-uterine device). Women who are using
•contraception will be required to have a pregnancy test (urine or serum) at the
•Screening Visit and at the Week 6/Exit Visit.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•Patients, who have/are
•a) received a dose of a product that contains or is metabolized to mesalamine by any route from which more than 1.6 g/day of mesalamine was available within 7 days before the Screening Visit;
•b) UC confined to rectum (isolated ulcerative proctitis);
•c) a history of allergy or hypersensitivity to salicylates, aminosalicylates, or any component of the Asacol tablet;
•d) a history or presence of any condition causing malabsorption or an effect on
•gastrointestinal motility or history of extensive small bowel resection (greater than one half the length of the small intestine) causing short bowel syndrome;
•e) a current abuser of drugs or alcohol;
•f) a history of HIV infection or AIDS;
•g) a significant co-existing illness or other condition(s) that, in the judgment of the
•Investigator, contraindicate(s) administration of the study drug and/or any study
•procedures;
•h) current renal disease (serum creatinine more than 1.5 times the upper limit of normal at Screening Visit) or documented history of hepatic disease (aspartate transaminase [AST] or alanine transaminase [ALT] more than 2 times the upper limit of normal);
•i) previously participated in this study;
•j) participated in any drug or device clinical study within 30 days before study entry;
•k) currently enrolled in any other clinical study;
•l) received any oral, intravenous, intramuscular, or rectally administered corticosteroids (including budesonide) within 30 days before the Screening Visit;
•m) received any other topical rectal therapy during the 7 days before the Screening Visit;
•n) received immunomodulatory therapy including, but not limited to, rosiglitazone,
•6-mercaptopurine, azathioprine, cyclosporine, or methotrexate within 90 days before the Screening Visit;
•o) received infliximab, certolizumab, or other biologic treatment of ulcerative colitis within 90 days before the Screening Visit;
•p) received antibiotics, other than topical antibiotics, within 7 days before the Screening Visit;
•q) used any product containing omega-3 (fish) oils within 7 days before the Screening Visit;
•r) received aspirin (except for cardioprotective reasons up to a maximum dose of
•325 mg/day) or other NSAIDs within 7 days before the Screening Visit;
•s) received any anti-diarrheals, and/or anti-spasmodics within 3 days before the Screening Visit;
•t) stool examination positive for Clostridium difficile, bacterial pathogens, or ova and
•u) if female, positive pregnancy test (serum or urine) or lactating

研究者

发起方

Procter & Gamble Technical Centres Limited

相似试验

进行中（未招募）

不适用

A double-blind, randomized, 6-week, parallel-group clinicaltrial to assess the safety and efficacy of Asacol 4.8 g/day(800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mgmesalamine tablet) for the treatment of moderately activeulcerative colitis (ASCEND III) - ASCEND IIIlcerative ColitisMedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerative

EUCTR2006-001310-32-LTProcter & Gamble Technical Centres Limited770

进行中（未招募）

不适用

EUCTR2006-001310-32-LVProcter & Gamble Technical Centres Limited470

进行中（未招募）

不适用

EUCTR2006-001310-32-HUProcter & Gamble Technical Centres Limited770

进行中（未招募）

不适用

EUCTR2006-001310-32-EEProcter & Gamble Technical Centres Limited770

进行中（未招募）

不适用

A trial evaluating compatibility and safety of FIAsp and insulin aspart with an external continuous subcutaneous insulin infusion system in adult subjects with type 1 diabetesDiabetes Mellitus, Type 1

EUCTR2013-002233-37-DEovo Nordisk A/S36